Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial

Table 2 Response to DC vaccination and results of immune monitoring

Pt. #	DC dose	Total No. vaccines	Response	Adverse effects	Proliferation assay	NK activity	IFN-r ELISPOT	CD4+25+cell proportion
R-M-1	5 × 10⁷	2	PD	No	↑↑	↑	-	↓
R-G-2	5 × 10⁷	2	SD	No	↑↑	↑	↑	↓
R-K-3	5 × 10⁷	3	PD	No	-	-	↑	↑
R-H-4	5 × 10⁷	2	PD	No	-	↑	-	-
R-N-5	5 × 10⁷	2	PD	No	-	↑	-	-
R-L-6	5 × 10⁷	2	PD	No	-	-	↓	-
B-S-1	5 × 10⁷	2	PD	No	↑	↑	↓	↑
B-H-2	5 × 10⁷	2	PD	No	↑	↑	-	↑
B-L-3	5 × 10⁷	2	PD	No	↑	-	↓	↑
B-Y-4	5 × 10⁷	2	PD	No	-	↓	-	-

↑↑: Highly significant (p < 0.001) increased ↑: Significant (p < 0.05) increased
↓: Significant (p < 0.05) decreased -: No significant change

ISSN: 1479-5876